Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
Jonathan Lopez, Marine Mommert, William Mouton, et al.
The Journal of Experimental Medicine (2021) Vol. 218, Iss. 10
Open Access | Times Cited: 120

Showing 26-50 of 120 citing articles:

Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease
Idoia Busnadiego, Irène A. Abela, Pascal M. Frey, et al.
PLoS Biology (2022) Vol. 20, Iss. 7, pp. e3001709-e3001709
Open Access | Times Cited: 52
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Mohd Arish, Wei Qian, Harish Narasimhan, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 46
Anti‐IFN‐α/‐ω neutralizing antibodies from COVID‐19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity
Federica Frasca, Mirko Scordio, Letizia Santinelli, et al.
European Journal of Immunology (2022) Vol. 52, Iss. 7, pp. 1120-1128
Open Access | Times Cited: 42
Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 561-585
Open Access | Times Cited: 34
TREM2+ and interstitial-like macrophages orchestrate airway inflammation in SARS-CoV-2 infection in rhesus macaques
Amit A. Upadhyay, Elise G. Viox, Timothy N. Hoang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 28
Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility
Benjamin G. Hale
European Journal of Immunology (2023) Vol. 53, Iss. 6
Open Access | Times Cited: 28
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
Quentin Philippot, Arnaud Fekkar, Adrian Gervais, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1093-1103
Open Access | Times Cited: 25
Innate immunity and interferon in SARS-CoV-2 infection outcome
Ram Savan, Michael Gale
Immunity (2023) Vol. 56, Iss. 7, pp. 1443-1450
Open Access | Times Cited: 25
Anti-cytokine autoantibodies: mechanistic insights and disease associations
Aristine Cheng, Steven M. Holland
Nature reviews. Immunology (2023) Vol. 24, Iss. 3, pp. 161-177
Closed Access | Times Cited: 25
Macrophage phagocytosis of SARS-CoV-2-infected cells mediates potent plasmacytoid dendritic cell activation
Obdulio García-Nicolás, Aurélie Godel, Gert Zimmer, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 7, pp. 835-849
Open Access | Times Cited: 24
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies
Sonja Fernbach, Nina K. Mair, Irène A. Abela, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 9
Open Access | Times Cited: 11
Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned
Giorgia Bucciol, Stuart G. Tangye, Isabelle Meyts
Current Opinion in Pediatrics (2021) Vol. 33, Iss. 6, pp. 648-656
Open Access | Times Cited: 53
The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders
Upasana Parthasarathy, Roberta Martinelli, Elisabeth H. Vollmann, et al.
Biochemical Pharmacology (2021) Vol. 195, pp. 114847-114847
Open Access | Times Cited: 45
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?
Ivan Zanoni
Current Opinion in Virology (2021) Vol. 50, pp. 119-127
Open Access | Times Cited: 41
Low baseline IFN-γ response could predict hospitalization in COVID-19 patients
Marion Crémoni, Jonathan Allouche, Daisy Graça, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection
Kami Pekayvaz, Alexander Leunig, Rainer Kaiser, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 29
The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)
Giuliana Giardino, Cinzia Milito, Vassilios Lougaris, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 5, pp. 935-946
Open Access | Times Cited: 29
Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
Rayhane Nchioua, Annika Schundner, Susanne Klute, et al.
Life Science Alliance (2023) Vol. 6, Iss. 6, pp. e202201745-e202201745
Open Access | Times Cited: 21
Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease
Charles E. Samuel
Journal of Biological Chemistry (2023) Vol. 299, Iss. 8, pp. 104960-104960
Open Access | Times Cited: 21
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques
Elise G. Viox, Timothy N. Hoang, Amit A. Upadhyay, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 20
Differences and similarities between innate immune evasion strategies of human coronaviruses
Helene Hoenigsperger, Rinu Sivarajan, Konstantin M. J. Sparrer
Current Opinion in Microbiology (2024) Vol. 79, pp. 102466-102466
Open Access | Times Cited: 8
A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist
Jérémie Le Pen, Gabrielle Paniccia, Volker Kinast, et al.
PLoS Biology (2024) Vol. 22, Iss. 9, pp. e3002767-e3002767
Open Access | Times Cited: 6
Treatments for COVID-19: Lessons from 2020 and new therapeutic options
Fanny Salasc, Thomas Lahlali, Emilie Laurent, et al.
Current Opinion in Pharmacology (2021) Vol. 62, pp. 43-59
Open Access | Times Cited: 33
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19
Jenny Garmendia, Alexis García, Claudia Valentina De Sanctis, et al.
Current Issues in Molecular Biology (2022) Vol. 45, Iss. 1, pp. 33-50
Open Access | Times Cited: 26
A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines
Naru Zhang, Kangchen Li, Zezhong Liu, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 387-387
Open Access | Times Cited: 25

Scroll to top